Lonza Group AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other
pharmaceutical manufacturers in Europe:
sales of 4.63 billion Euro [US$5.10 billion]
of which 31%
H. Lundbeck A/S
(18.12 billion Danish Kroner [US$2.67 billion]
of which 100%
was Pharmaceuticals), and
based in Russia
(251.73 billion Russian Rubles [US$3.91 billion]
of which 72%
During the year ended December of 2018, sales at
Lonza Group AG were 5.54 billion Swiss Francs (US$5.60 billion).
increase of 8.6%
versus 2017, when the company's sales were 5.11 billion Swiss Francs.
This was the fifth consecutive year of sales increases at Lonza Group AG
(and since 2013, sales have increased a total of 55%).
Sales of Pharma&biotech saw an increase
that was more than double the company's growth rate: sales were up
46.6% in 2018, from
2.12 billion Swiss Francs to 3.11 billion Swiss Francs.
Not all segments of Lonza Group AG experienced an increase in sales in 2018:
sales of Specialty Ingredients fell 0.4% to 2.39 billion Swiss Francs.